Indiplon NDA Expected Mid-Year; Neurocrine Reports Positive Long-Term Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Neurocrine Biosciences and Pfizer expect to submit NDAs for immediate- and modified-release formulations of their sleep agent indiplon by June.